Image

Global Iron-Deficiency Anemia Therapy Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Iron-Deficiency Anemia Therapy Market

Market Analysis and Size

In recent years, the iron-deficiency anemia therapy market is anticipated to grow rapidly during the forecast period. According to the World Health Organization, anemia affects between 1.5 and 1.74 billion people globally, with iron deficiency accounting for half of all anemia cases. The worldwide iron-deficiency anemia therapy market is expected to benefit from the increasing prevalence of iron deficiency anemia. During the continuing COVID-19 pandemic, iron metabolism and anemia may play a key role in various organ failure. Coronavirus is more contagious in patients who are iron deficient. As a result, firms in the -deficiency anemia therapy market have raised their output capacity to avoid medicine supply shocks at pharmacies and hospitals.

Data Bridge Market Research analyses that the iron-deficiency anemia therapy market was valued at USD 3,166.05 million in 2021 and is expected to reach USD 11041.65 million by 2029, registering a CAGR of 16.9% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Iron deficiency anemia is a kind of anemia that occurs when the body's iron stores are depleted. Anemia is indicated by an inadequacy of healthy red blood cells. RBCs supply oxygen to human tissues. Iron, which is found in red blood cells, is important in the production of haemoglobin. Haemoglobin deficiency indicates a lack of oxygen in the body. It's critical to keep your iron levels in check. Consumption of iron-rich foods such as fruits, meat, vegetables, and cereals can help to treat or prevent iron deficiency. Vitamin C can help to avoid iron deficiency.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (US), Akebia Therapeutics, INC. (US), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (UK), Advanz Pharmaceutical (UK), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (UK)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Iron-deficiency Anemia Therapy Market Dynamics

Drivers

  • Increasing prevalence of iron-deficiency anemia

The rising prevalence of iron-deficiency anemia is estimated to influence the market's growth rate. Along with this, the growing incidences of chronic kidney diseases will influence the market dynamics during the forecast period.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of iron-deficiency anemia therapy market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the iron-deficiency anemia therapy market. Additionally, high disposable income and increase in the risk of haemodilution will expand iron-deficiency anemia therapy market. Along with this, rising geriatric population and sedentary lifestyle of people will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the iron-deficiency anemia therapy market growth. Along with this, rising drug approvals and launches will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the iron-deficiency anemia therapy market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the therapy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the iron-deficiency anemia therapy market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Iron-deficiency anemia therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Iron-deficiency Anemia Therapy Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems worldwide have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of multiple sclerosis in recent months.

Recent Development

  • In June 2021, Sandoz announced the launch of the first generic high dose intravenous iron named Ferumoxytol Injection, which is used to treat US patients suffering from iron deficiency anemia. Ferumoxytol, a generic version of AMAG Pharmaceuticals' Feraheme (ferumoxytol injection), is approved to treat IDA in adults with an intolerance to oral iron, a poor response to oral iron, or chronic kidney disease.

Global Iron-deficiency Anemia Therapy Market Scope

The iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

  • Parenteral Iron Therapy
  • Oral Iron Therapy

Therapy Areas

  • Inflammatory Bowel Disease
  • Renal
  • Obstetrics and Gynecology
  • Congestive Heart Failure (CHF)
  • Oncology
  • Others

Population

  • Adults
  • Pediatric
  • Geriatric

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Iron-deficiency Anemia Therapy Market Regional Analysis/Insights

The Iron-deficiency anemia therapy market is analysed and market size insights and trends are provided by country, therapy, therapy areas, population, end-users and distribution channel as referenced above.

The countries covered in the Iron-deficiency anemia therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the iron-deficiency anemia therapy market because of the well-established healthcare infrastructure in this region. Additionally, growing focus of major key players on novel technology will further propel the 'market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Iron-deficiency Anemia Therapy Market Share Analysis

The Iron-deficiency anemia therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to iron-deficiency anemia therapy market.

Some of the major players operating in the iron-deficiency anemia therapy market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Ireland)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (US)
  • Fresenius SE & Co. KGaA (Germany)
  • Lupin (India)
  • ViforPharma Ltd. (Switzerland)
  • AMAG Pharmaceuticals (US)
  • Akebia Therapeutics, INC. (US)
  • CHO-A Pharmaceutical CO., LTD. (South Korea)
  • Orion Corporation (Finland)
  • Pharmacosmos A/S (Denmark)
  • Shield Therapeutics (UK)
  • Advanz Pharmaceutical (UK)
  • Alkem Labs (India)
  • Zydus Cadila (India)
  • Hikma Pharmaceuticals PLC (UK)


SKU-
Why Choose Us


Frequently Asked Questions

The market value for Iron-Deficiency Anemia Therapy Market is expected USD 11041.65 million by 2029.
The Iron-Deficiency Anemia Therapy Market is to grow at a CAGR of 16.9% during the forecast by 2029.
The expansion of the Iron-Deficiency Anemia Therapy Market will be fueled by the changing lifestyle of people and rising prevalence of iron-deficiency anemia. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global iron-deficiency anemia therapy market.
The major players operating in the Iron-Deficiency Anemia Therapy Market are Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (US), Akebia Therapeutics, INC. (US), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (UK), Advanz Pharmaceutical (UK), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (UK).